Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nature Reviews. Immunology|September 6, 2014
Dendritic cell-targeted vaccines--hope or hype?Wolfgang Kastenmüller, Kathrin Kastenmüller, Christian Kurts, et al.
Drugs & Aging|May 9, 2018
Potential Drug-Drug Interactions in a Cohort of Elderly, Polymedicated Primary Care Patients on Antithrombotic TreatmentKatharina Luise Schneider, Kathrin Kastenmüller, Klaus Weckbecker, et al.
Mediators of Inflammation|April 13, 2012
Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cellsMatthias Sauter, Kathrin Kastenmüller, Franziska Belling, et al.
Thrombosis and Haemostasis|June 4, 2009
Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesisMarkus Wörnle, Matthias Sauter, Kathrin Kastenmüller, et al.
Applied Biochemistry and Biotechnology|May 28, 2009
Role of toll-like receptor 3, RIG-I, and MDA5 in the expression of mesothelial IL-8 induced by viral RNAMarkus Wörnle, Matthias Sauter, Kathrin Kastenmüller, et al.
Infection and Immunity|June 25, 2008
Decreased susceptibility of mice to infection with Listeria monocytogenes in the absence of interleukin-18Matthias Lochner, Kathrin Kastenmüller, Michael Neuenhahn, et al.
Cell Biology International|November 11, 2008
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesotheliomaMarkus Wörnle, Matthias Sauter, Kathrin Kastenmüller, et al.
Molecular and Cellular Biochemistry|November 14, 2008
Novel role of toll-like receptor 3, RIG-I and MDA5 in poly (I:C) RNA-induced mesothelial inflammationMarkus Wörnle, Matthias Sauter, Kathrin Kastenmüller, et al.
European Journal of Immunology|May 10, 2008
Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunityAntje Heit, Friedemann Gebhardt, Katharina Lahl, et al.
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)-Never Change a Running System?Katja S Just, Catharina Scholl, Miriam Boehme, et al.
Pageof 2